Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs, and Others), Type (Prescription-Based Drugs and Over-the-Counter Drugs): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-06
- Report ID: 1419
- Pages: 202
-
Format:
The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026.
Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extra-articular organs. Furthermore, this medical condition is often progressive and results in pain, stiffness, and swelling of joints. Moreover, there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a persons overall function. This is achieved through pain medication, steroids, and NSAIDs that are frequently used to help with the symptoms. In addition, disease-modifying anti-rheumatic drugs (DMARDs) are used to slow down the progression of this disease. These drugs are the primary treatment for RA and have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. However, early diagnosis and early treatment is the key for better management of the disease. Recent advancements with biosimilars, which may be used to treat RA and increase in approvals of the same by regulatory authorities have opened new avenues for the anti-rheumatics market.
The major factors that fuel the growth of the global rheumatoid arthritis drugs market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of anti-rheumatic market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the RA drugs market.
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Drug Class
o Disease Modifying Anti-rheumatic Drugs (DMARD's)
o Nonsteroidal Anti-inflammatory Drugs (NSAID's)
o Corticosteroids
o Uric Acid Drugs
o Others
By Type
o Prescription-Based Drugs
o Over-the-Counter Drugs
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
Pfizer, Inc.
Johnson & Johnsons
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Celegene Corporations
MedImmune, LLC
Takeda Pharmaceutical Company Ltd.
Biogen Inc.
Celltrion Inc.
Amgen Inc
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Sebela Pharmaceuticals
Abbott LaboratoriesSafe In Breastfeeding
Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.2.1. List of Key Players Profiled In The Report
1.3. Research Methodology
1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Top Player Positioning
3.2.1. Top Investment Pockets
3.3. Key Forces Shaping Anti-Rheumatics Industry/Market
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Surge In Geriatric Population Across The Globe
3.4.1.2. Surge In Healthcare Expenditure Worldwide
3.4.1.3. Rise In Prevalence of Rheumatoid Arthritis Across The Globe
3.4.2. Restraint
3.4.2.1. Patent Expirations of Blockbuster Drugs
3.4.3. Opportunity
3.4.3.1. High Growth Potential In Developing Economies
3.4.4. Impact Analyses
Chapter 4: Anti-Rheumatics Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Disease Modifying Anti-Rheumatic Drugs
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis By Country
4.3. Nonsteroidal Anti-Inflammatory Drugs
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis By Country
4.4. Corticosteroids
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis By Country
4.5. Uric Acid Drugs
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis By Country
4.6. Others
4.6.1. Key Market Trends, Growth Factors, And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis By Country
Chapter 5: Anti-Rheumatics Market, By Type
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Prescription-Based Drugs
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis By Country
5.3. Over-The-Counter Drugs
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis By Country
Chapter 6: Anti-Rheumatics Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends And Opportunities
6.2.2. Market Analysis, By Country
6.2.2.1. U.S.
6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.1.2. U.S. Market Size And Forecast, By Type
6.2.2.2. Canada
6.2.2.2.1. Canada Market Size And Forecast, By Drug Class
6.2.2.2.2. Canada Market Size And Forecast, By Type
6.2.2.3. Mexico
6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
6.2.2.3.2. Mexico Market Size And Forecast, By Type
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Type
6.3. Europe
6.3.1. Key Market Trends And Opportunities
6.3.2. Market Analysis, By Country
6.3.2.1. Germany
6.3.2.1.1. Germany Market Size And Forecast, By Drug Class
6.3.2.1.2. Germany Market Size And Forecast, By Type
6.3.2.2. France
6.3.2.2.1. France Market Size And Forecast, By Drug Class
6.3.2.2.2. France Market Size And Forecast, By Type
6.3.2.3. Uk
6.3.2.3.1. Uk Market Size And Forecast, By Drug Class
6.3.2.3.2. Uk Market Size And Forecast, By Type
6.3.2.4. Italy
6.3.2.4.1. Italy Market Size And Forecast, By Drug Class
6.3.2.4.2. Italy Market Size And Forecast, By Type
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
6.3.2.5.2. Rest of Europe Market Size And Forecast, By Type
6.3.3. Europe Market Size And Forecast, By Drug Class
6.3.4. Europe Market Size And Forecast, By Type
6.4. Asia-Pacific
6.4.1. Key Market Trends And Opportunities
6.4.2. Market Analysis, By Country
6.4.2.1. Japan
6.4.2.1.1. Japan Market Size And Forecast, By Drug Class
6.4.2.1.2. Japan Market Size And Forecast, By Type
6.4.2.2. China
6.4.2.2.1. China Market Size And Forecast, By Drug Class
6.4.2.2.2. China Market Size And Forecast, By Type
6.4.2.3. India
6.4.2.3.1. India Market Size And Forecast, By Drug Class
6.4.2.3.2. India Market Size And Forecast, By Type
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Type
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Type
6.5. Lamea
6.5.1. Key Market Trends And Opportunities
6.5.2. Market Analysis, By Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.1.2. Brazil Market Size And Forecast, By Type
6.5.2.2. South Africa
6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
6.5.2.2.2. South Africa Market Size And Forecast, By Type
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Type
6.5.2.4. Rest of Lamea
6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Type
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Type
Chapter 7: Company Profiles
7.1. Abbvie Inc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.1.6. Key Strategic Moves And Developments
7.2. Amgen Inc.
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bristol-Myers Squibb Company
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Eli Lilly And Company
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments
7.5. F. Hoffmann-La Roche Ltd.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Johnson & Johnson
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Merck & Co., Inc
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Novartis Ag
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.8.6. Key Strategic Moves And Developments
7.9. Pfizer Inc.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves And Developments
7.10. Ucb S.A.
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.6. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
